We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


GATC Biotech to Sequence 100,000 Human Genomes by 2014

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "GATC Biotech to Sequence 100,000 Human Genomes by 2014"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:
Within the next four years GATC Biotech plans to analyze 100,000 human genomes in particular for the pharmaceutical and diagnostic industry as well as for academic research. This will be realized by applying Illumina’s HiSeq 2000 as well as GATC Biotech’s latest acquisition, the single molecule sequencing platform PacBio RS.

To achieve this goal, GATC Biotech expands its business portfolio by opening a business unit for human genome analysis. This new strategic unit is located in the company’s German headquarters and focuses on the sequencing and bioinformatic analysis of human samples of all sizes; from small enriched regions to entire genomes.

“By the end of 2010 we will have analyzed more than 100 human genomes, an even higher number as announced in 2007,” comments Dr. Kerstin Stangier, Director Business Development and head of the new business unit.

“Based on this experience and know-how, we can offer highest flexibility and quality as well as short delivery times. The new business unit includes a LIMS controlled production workflow with automated library preparation and an extensive bioinformatics pipeline which can be adapted to any project goal. Current collaborations, for example with the International Cancer Genome Consortium, have been very helpful for the development of this pipeline.”